STANDARD BIOTOOLS INC
LAB · NASDAQ
Updated at 2026-10-15 16:18:44
- Today's High
- $0.66
- Today’s Low
- $0.63
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $0.64
- Previous Close
- $0.63
- Volume
- 1.18M
- Market Cap
- $248.11M
- P/E Ratio
- 3.04X
- EPS
- $0.21
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Life Sciences Tools & Services
- Sub-industry
- MEDICAL DEVICES
- Headquarters
- 50 MILK STREET, BOSTON, MA, UNITED STATES, 02109
- Country
- US
- Listing Date
- 2011-02-10
- Fiscal Year End
- December
- Shares Outstanding
- 391.46M
- CIK
- 0001162194
- Website
- www.standardbio.com
Standard Biotools Inc. (LAB) is a pioneering biotechnology company dedicated to enhancing genomic analysis and biological research through cutting-edge tools and technologies. The firm's focus on developing high-performance products for laboratories in genomics and proteomics is aimed at improving research precision and operational efficiency. Utilizing proprietary platforms, Standard Biotools accelerates scientific discoveries, reinforcing its position as a leader in the dynamic biotechnology landscape. With a commitment to meeting the growing demand for innovative analytical solutions, LAB is strategically positioned to facilitate significant advancements within the life sciences sector.
Financial Metrics
Revenue
2026-06-30
$20.1M
2026-03-31
$21.14M
2025-12-31
$23.79M
2025-09-30
$19.55M
Operating Expenses
2026-06-30
$35.92M
2026-03-31
$20.72M
2025-12-31
$32.16M
2025-09-30
$32.95M
Net Income
2026-06-30
-$26.75M
2026-03-31
-$45.22M
2025-12-31
$19.28M
2025-09-30
-$34.68M
Net Profit Margin
2026-06-30
-133.09%
2026-03-31
-213.85%
2025-12-31
81.03%
2025-09-30
-177.4%
Earnings Per Share
2026-06-30
$-0.05
2026-03-31
$-0.02
2025-12-31
$0.06
2025-09-30
$-0.04
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$28.06M
2026-03-31
-$13.2M
2025-12-31
-$20.73M
2025-09-30
-$31.36M
Effective Tax Rate
2026-06-30
-0.41%
2026-03-31
-0.07%
2025-12-31
163.09%
2025-09-30
3.69%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $20.1M | $21.14M | $23.79M | $19.55M |
| Operating Expenses | $35.92M | $20.72M | $32.16M | $32.95M |
| Net Income | -$26.75M | -$45.22M | $19.28M | -$34.68M |
| Net Profit Margin | -133.09% | -213.85% | 81.03% | -177.4% |
| Earnings Per Share | $-0.05 | $-0.02 | $0.06 | $-0.04 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$28.06M | -$13.2M | -$20.73M | -$31.36M |
| Effective Tax Rate | -0.41% | -0.07% | 163.09% | 3.69% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.